# Prolira

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/prolira-b-v

- Industry: Medical Devices & Equipment
- Headquarters: Utrecht, Netherlands
- Website: www.prolira.com
- Latest round: Series A (Nov 1, 2018)
- Investors on record: 4

## About

Based in the Netherlands, Prolira B.V. specializes in the development and distribution of innovative medical devices aimed at enhancing brain health monitoring, particularly through the DeltaScan® Brain State Monitor.Prolira B.V. was founded in 2015 and is headquartered in Utrecht, Netherlands. The company is focused on developing medical devices for detecting acute encephalopathy and delirium. The CEO, Dominic Spadafore, leads the firm, which has undergone no significant pivots or changes in operations since its inception. Prolira has engaged in a total of three funding rounds, with the most recent round occurring in February 2022, where the company raised EUR 5.000 mn, led by StartGreen Capital and included investors such as Health Innovations, Holland Capital, Oost NL, and ROM Utrecht Region. This funding round brought the total amount raised by Prolira to EUR 5.000 mn.Prolira specializes in the development and distribution of the DeltaScan® Brain State Monitor, an FDA-cleared and EU MDR certified device designed for the rapid detection of acute encephalopathy and delirium—conditions affecting millions of patients. The DeltaScan® technology enables clinicians to conduct objective measurements of brain health, facilitating timely interventions that may improve patient outcomes, often before symptoms manifest. Targeted primarily at hospitals and healthcare providers, the product serves a diverse clientele that includes surgical and intensive care units across Europe and the United States, where approximately 50% of surgical and ICU patients face the risk of developing these cognitive impairments. The device is particularly relevant in a healthcare landscape where the annual costs associated with acute brain failure are estimated to rival those of heart disease and diabetes, highlighting its critical role in enhancing delirium management and neurotoxicity monitoring during treatments.Prolira's revenue model is built upon direct sales of its flagship product, the DeltaScan® Brain State Monitor, to healthcare institutions, predominantly in the European and U.S. markets. The company engages in business-to-business transactions, supplying hospitals and clinics with necessary equipment for monitoring brain health, thereby enabling timely clinical decision-making for patients at risk of acute encephalopathy and delirium. This transactional structure involves one-time purchases, with potential agreements for service and maintenance support that accompany the devices. The pricing strategy for the DeltaScan® product is structured to reflect its advanced technology and the critical healthcare needs it addresses, providing healthcare providers with a valuable tool for improving patient management and outcomes.In February 2022, Prolira B.V. raised EUR 5.000 mn in venture funding, led by new investor Borski Fund, with participation from ROM Utrecht Region. The company plans to utilize this funding to expand its market reach in the Netherlands, Germany, the UK, and the US. Future initiatives include the development of new products aimed at enhancing brain health monitoring, alongside an ambitious strategy to penetrate these key markets by leveraging the latest funding.

## Funding rounds

- Series A, Nov 1, 2018 — Morgan Holland Venture Partners, Oost NL, Health Innovations
- Seed, Sep 27, 2016 — Holland Capital, Health Innovations

## Investors

- Holland Capital (https://capitalatlas.ai/funds/holland-capital) — Seed
- Health Innovations (https://capitalatlas.ai/funds/health-innovations) — Seed, Series A
- Morgan Holland Venture Partners — Series A
- Oost NL (https://capitalatlas.ai/funds/oost-nl) — Series A